Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?

European Journal of Clinical Pharmacology

Volumn 72, Issue 9, 2016, Pages 1125-1134

  Desmaele, S ^a   Steurbaut, S ^a   Cornu, P ^a   Brouns, R ^b   Dupont, A G ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Direct oral anticoagulants; Inclusion criteria; Indications; Summary of product characteristics

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN ETEXILATE; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; RIVAROXABAN; THIENOPYRIDINE DERIVATIVE; WARFARIN; ANTICOAGULANT AGENT; DABIGATRAN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE REGISTRY; DRUG CONTRAINDICATION; DRUG INDICATION; FEMALE; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; STROKE PATIENT; CLINICAL TRIAL (TOPIC); MIDDLE AGED; ORAL DRUG ADMINISTRATION; STROKE; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; DABIGATRAN; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE;

EID: 84976271567     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-016-2078-1     Document Type: Article

References (24)

1. BayerPharmaAG (2013) Summary of product characteristics: Xarelto
2. Bristol-MyersSquibb/Pfizer/EEIG B-M (2011) Summary of product characteristics: Eliquis
3. BoehringerIngelheimInternationalGmbH (2013) Summary of product characteristics: Pradaxa
4. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blomstrom-Lundqvist C, Colonna P, De Sutter J, Ernst S, Goette A, Gorenek B, Hatala R, Heidbuchel H, Heldal M, Kristensen SD, Le Heuzey JY, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt FW (2012) 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33(21):2719–2747. doi:10.1093/eurheartj/ehs253
5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891. doi:10.1056/NEJMoa1009638
6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992. doi:10.1056/NEJMoa1107039
7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151. doi:10.1056/NEJMoa0905561
8. Dogliotti A, Giugliano RP (2015) A novel approach indirectly comparing benefit–risk balance across anti-thrombotic therapies in patients with atrial fibrillation. Eur Heart J – Cardiovasc Pharma 1(1):15–28. doi:10.1093/ehjcvp/pvu007
9. Gheorghe A, Roberts TE, Ives JC, Fletcher BR, Calvert M (2013) Centre selection for clinical trials and the generalisability of results: a mixed methods study. PLoS One 8(2):e56560. doi:10.1371/journal.pone.0056560
10. Rothwell PM (2005) External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet 365(9453):82–93. doi:10.1016/s0140-6736(04)17670-8
11. EMA (2012) Concept paper on extrapolation of efficacy and safety in medicine development
12. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG (2015) XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. doi:10.1093/eurheartj/ehv466
13. Lee S, Monz BU, Clemens A, Brueckmann M, Lip GY (2012) Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the general practice research database. BMJ Open 2(6). doi:10.1136/bmjopen-2012-001768
14. Hagg L, Johansson C, Jansson JH, Johansson L (2014) External validity of the ARISTOTLE trial in real-life atrial fibrillation patients. Cardiovasc Ther 32(5):214–218. doi:10.1111/1755-5922.12087
15. Hylek EM, D’Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S (2006) Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke; J Cereb Circ 37(4):1075–1080. doi:10.1161/01.STR.0000209239.71702.ce
16. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH (2010) Guidelines for the management of atrial fibrillation: the task force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31(19):2369–2429. doi:10.1093/eurheartj/ehq278
17. Yates SW (2013) Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient. Int J Gen Med 6:167–180. doi:10.2147/IJGM.S39379
18. Gross CP, Vogel EW, Dhond AJ, Marple CB, Edwards RA, Hauch O, Demers EA, Ezekowitz M (2003) Factors influencing physicians’ reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther 25(6):15
19. ZorginstituutNederland (2016) Medicijnkosten. http://www.medicijnkosten.nl/default.asp
20. Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, Michalski F, Kohler C, Werth S, Sahin K, Tittl L, Hansel U, Weiss N (2014) Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 124(6):955–962. doi:10.1182/blood-2014-03-563577
21. Tamayo S, Frank Peacock W, Patel M, Sicignano N, Hopf KP, Fields LE, Sarich T, Wu S, Yannicelli D, Yuan Z (2015) Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol 38(2):63–68. doi:10.1002/clc.22373
22. Russo V, Bianchi V, Cavallaro C, Vecchione F, De Vivo S, Santangelo L, Sarubbi B, Calabro P, Nigro G, D’Onofrio A (2015) Efficacy and safety of dabigatran in a “real-life” population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry. Eur Rev Med Pharmacol Sci 19(20):3961–3967
23. Eikelboom JW, Weitz JI (2015) ‘Realworld’ use of non-vitamin K antagonist oral anticoagulants (NOACs): lessons from the Dresden NOAC registry. Thromb Haemost 113(6):1159–1161. doi:10.1160/TH15-02-0158
24. Avgil-Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Behlouli H, Pilote L (2015) Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost 115(1):152–160. doi:10.1160/TH15-03-0247